Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY24 results · Jan–Mar 2024
Bliss GVS Pharma reported revenue from operations of ₹198.13 crore (up 7.2% from Q4 FY23) and net loss of ₹4.91 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 198.13 | 184.78 | +7.2% | 200.72 | −1.3% |
| Other income | 5.60 | 2.98 | +88.0% | 5.42 | +3.3% |
| Total income | 203.73 | 187.76 | +8.5% | 206.14 | −1.2% |
| Profit before tax | (3.95) | (0.75) | Loss widened | 40.04 | Turned loss |
| Net profit for the period | (4.91) | 3.46 | Turned loss | 29.07 | Turned loss |
| Attributable to shareholders of the company | (9.15) | 3.34 | Turned loss | 27.61 | Turned loss |
| EPS, basic (₹) | (0.88) | 0.34 | Turned loss | 2.64 | Turned loss |
| Net margin (%) | -2.5 | 1.9 | 14.5 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.82 | 143.42 | +14.2% | 161.33 | +1.5% |
| Other income | 8.46 | 6.48 | +30.6% | 7.90 | +7.2% |
| Total income | 172.28 | 149.90 | +14.9% | 169.23 | +1.8% |
| Profit before tax | (15.23) | 8.44 | Turned loss | 28.52 | Turned loss |
| Net profit for the period | (11.46) | 6.11 | Turned loss | 20.72 | Turned loss |
| EPS, basic (₹) | (1.11) | 0.60 | Turned loss | 1.99 | Turned loss |
| Net margin (%) | -7.0 | 4.3 | 12.8 |
Consolidated
- Filed with BSE
- 09 May 2024, 13:02 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 May 2024, 13:02 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE